248 results on '"Garovoy, Marvin"'
Search Results
2. Phase 1 Healthy Volunteer Study of AL01211, an Oral, Non‐brain Penetrant Glucosylceramide Synthase Inhibitor, to Treat Fabry Disease and Type 1 Gaucher Disease
3. Subcutaneous efalizumab is not effective in the treatment of alopecia areata
4. Pharmacokinetic–Pharmacodynamic–Efficacy Analysis of Efalizumab in Patients with Moderate to Severe Psoriasis
5. An overview of the pharmacokinetics and pharmacodynamics of efalizumab: a monoclonal antibody approved for use in psoriasis
6. Increase in TNF-[alpha] and inducible nitric oxide synthase-expressing dendritic cells in psoriasis and reduction with efalizumab (anti-CD11a)
7. Subcutaneously Administered Efalizumab (Anti-CD11a) Improves Signs and Symptoms of Moderate to Severe Plaque Psoriasis
8. A novel targeted T-cell modulator, efalizumab, for plaque psoriasis
9. Population Pharmacokinetics and Pharmacodynamics of the Anti-CD11a Antibody hu1124 in Human Subjects with Psoriasis
10. Self determinant selection and acquisition of the autoimmune T cell repertoire
11. Transitioning patients from efalizumab to alternative psoriasis therapies: findings from an open-label, multicenter, Phase IIIb study
12. Are blood transfusions beneficial in the cyclosporine era?
13. Microtubule Function in Immune and Nonimmune Lymphocyte-Mediated Cytotoxicity
14. Psoriasis as a Model for T-Cell–Mediated Disease : Immunobiologic and Clinical Effects of Treatment With Multiple Doses of Efalizumab, an Anti–CD11a Antibody
15. The treatment of moderate to severe psoriasis with a new anti-CD11a monoclonal antibody
16. Flow cytometry crossmatching as a predictor of acute rejection in sensitized recipients of cadaveric renal transplants
17. Non-inherited maternal HLA antigens and protection against sensitisation
18. Anti-adhesion antibodies: Efalizumab, a humanized anti-CD11a monoclonal antibody
19. Effects of administration of a single dose of a humanized monoclonal antibody to CD11a on the immunobiology and clinical activity of psoriasis
20. Immunological Monitoring and Renal Transplantation
21. Genetic variation in aryl N ‐acetyltransferase results in significant differences in the pharmacokinetic and safety profiles of amifampridine (3,4‐diaminopyridine) phosphate
22. Recurrent Systemic Lupus Erythematosus Involving Renal Allografts
23. Efalizumab for the Treatment of Psoriatic Arthritis
24. Increase in TNF-α and inducible nitric oxide synthase-expressing dendritic cells in psoriasis and reduction with efalizumab (anti-CD11a)
25. Safety of efalizumab in patients with psoriatic arthritis: results of a phase II, randomized, double-blind, placebo-controlled study
26. Subcutaneously Administered Efalizumab (Anti-CD 11a) Improves Signs and Symptoms of Moderate to Severe Plaque Psoriasis
27. Adhesion molecules as therapeutic targets for autoimmune diseases and transplant rejection
28. Anti-adhesion antibodies
29. Genetic variation in aryl N-acetyltransferase results in significant differences in the pharmacokinetic and safety profiles of amifampridine (3,4-diaminopyridine) phosphate.
30. HLA Compatibility Requirements for CD8+-T-Cell-Mediated Suppression of Human Immunodeficiency Virus Replication
31. Differential Activation of T Cells by Natural Antigen Peptide Analogues: Influence on Autoimmune and Alloimmune In Vivo T Cell Responses
32. Phase I trial of psoriasis with an anti-CD11A (LFA-1) monoclonal antibody (MAB)
33. In utero hematopoietic stem cell transplants prolong survival of postnatal kidney transplantation in monkeys
34. A PHASE I TRIAL OF HUMANIZED ANTI-INTERLEUKIN 2 RECEPTOR ANTIBODY IN RENAL TRANSPLANTATION1
35. Reply: THE FLOW CYTOMETRY CROSSMATCH IN SECOND KIDNEY GRAFTS
36. AN OLIGONUCLEOTIDE BLOCKS INTERFERON-?? SIGNAL TRANSDUCTION1
37. The Use of Intravenous Immunoglobulin in Recurrent Pregnancy Loss Associated With Combined Alloimmune and Autoimmune Abnormalities
38. IDENTIFICATION OF HIGH- AND LOW-RISK SECOND KIDNEY GRAFTS
39. INDUCTION OF T CELL RESPONSES TO A SELF-ANTIGEN FOLLOWING ALLOTRANSPLANTATION1
40. Immunopharmacodynamic Studies of Cyclosporine in Patients Awaiting Renal Transplantation
41. Suppression of interferon-γ induction of MHC class II and ICAM-1 by a 26-base oligonucleotide composed of deoxyguanosine and deoxythymidine
42. Positive impact of DNA typing on solid organ transplantation
43. Report of the second international soluble HLA (sHLA) workshop
44. INHIBITION OF INTERFERON-γ-MEDIATED IMMUNE FUNCTIONS BY OLIGONUCLEOTIDES
45. INHIBITION OF INTERFERON-γ-INDUCED MAJOR HISTOCOMPATIBILITY COMPLEX CLASS I EXPRESSION BY CERTAIN OLIGODEOXYNUCLEOTIDES
46. Biological availability and nuclease resistance extend thein vitroactivity of a phosphorothioate-3′hydroxypropylamine oligonucleotide
47. Flow cytometry crossmatching: The first 10 years
48. In vivogeneration of highly abundant sequence-specific oligonucleotides for antisense and triplex gene regulation
49. Characteristics of Oligonucleotide Uptake in Human Keratinocyte Cultures
50. Associations of HLA-DR and HLA-DQ types with anti-GBM nephritis by sequence-specific oligonucleotide probe hybridization
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.